Next Article in Journal
Methylene Blue Is a Nonspecific Protein–Protein Interaction Inhibitor with Potential for Repurposing as an Antiviral for COVID-19
Next Article in Special Issue
Accurate Mass Identification of an Interfering Water Adduct and Strategies in Development and Validation of an LC-MS/MS Method for Quantification of MPI8, a Potent SARS-CoV-2 Main Protease Inhibitor, in Rat Plasma in Pharmacokinetic Studies
Previous Article in Journal
Inhibition of Human Respiratory Influenza A Virus and Human Betacoronavirus-1 by the Blend of Double-Standardized Extracts of Aronia melanocarpa (Michx.) Elliot and Sambucus nigra L.
Previous Article in Special Issue
Immunosuppressant Therapies in COVID-19: Is the TNF Axis an Alternative?
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 15
Issue 5
10.3390/ph15050620
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Discovery of Natural Lead Compound from Dendrobium sp. against SARS-CoV-2 Infection

by
Jutamas Jiaranaikulwanitch
1,2,
Wipawadee Yooin
1,2,
Nopporn Chutiwitoonchai
3,
Worathat Thitikornpong
4,5,6,
Boonchoo Sritularak
5,7,
Pornchai Rojsitthisak
4,5,6 and
Opa Vajragupta
5,6,*
1
Center of Excellence for Innovation in Analytical Science and Technology for a Biodiversity-Based Economic and Society (I-ANALY-S-T_B.BES-CMU), Chiang Mai University, Chiang Mai 50200, Thailand
2
Department of Pharmaceutical Sciences, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand
3
Veterinary Health Innovation and Management Research Group, National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Bangkok 12120, Thailand
4
Department of Food and Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand
5
Center of Excellence in Ageing and Chronic Diseases, Chulalongkorn University, Bangkok 10330, Thailand
6
Molecular Probes for Imaging Research Network, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand
7
Department of Pharmacognosy, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2022, 15(5), 620; https://0-doi-org.brum.beds.ac.uk/10.3390/ph15050620
Submission received: 16 April 2022 / Revised: 7 May 2022 / Accepted: 10 May 2022 / Published: 18 May 2022
(This article belongs to the Special Issue COVID-19 in Pharmaceuticals)
Browse Figures
Versions Notes

Abstract

:
Since the pandemic of severe acute respiratory syndrome coronavirus (SARS-CoV-2) in December 2019, the infection cases have quickly increased by more than 511 million people. The long epidemic outbreak over 28 months has affected health and economies worldwide. An alternative medicine appears to be one choice to alleviate symptoms and reduce mortality during drug shortages. Dendrobium extract is one of the traditional medicines used for COVID-19 infection. Several compounds in Dendrobium sp. had been reported to exert pharmacological activities to treat common COVID-19-related symptoms. Herein, in silico screening of 83 compounds from Dendrobium sp. by using the SARS-CoV-2 spike protein receptor-binding domain (RBD) as a drug target was performed in searching for a new lead compound against SARS-CoV-2 infection. Four hit compounds showing good binding affinity were evaluated for antiviral infection activity. The new lead compound DB36, 5-methoxy-7-hydroxy-9,10-dihydro-1,4-phenanthrenequinone, was identified with the IC50 value of 6.87 ± 3.07 µM. The binding mode revealed that DB36 bound with the spike protein at the host receptor, angiotensin-converting enzyme 2 (ACE2) binding motif, resulted in antiviral activity. This study substantiated the use of Dendrobium extract for the treatment of SARS-CoV-2 infection and has identified new potential chemical scaffolds for further drug development of SARS-CoV-2 entry inhibitors.

1. Introduction

The pandemic of COVID-19 disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2) has affected health and economies worldwide. By 3 May 2022, 511,965,711 confirmed cases of COVID-19 and 6,240,619 deaths had been reported by WHO since the first case was reported (WHO, https://covid19.who.int (accessed on 5 May 2022)). The number of infection cases is still increasing continuously. Due to the lack of effective and specific antiviral drugs against SARS-CoV-2, the discovery of new lead compounds is urgently needed. Among various natural products, medicinal herbs, the most frequently used for drug discovery, are the most essential and abundant sources of bioactive compounds [1]. Dendrobium sp. is a plant that has been used in traditional Chinese medicine (TCM) for thousands of years to nourish Yin, increasing the production of body fluids and heat-clearing [2,3]. “Shihu” is the common name of thirty Dendrobium species such as D. nobile, D. chrysotoxum, D. fimbriatum and others [4]. Another common name of TCM from D. officinale is “Tiepi shihu” [3]. The monographs of both Shihu and Tiepi shihu were officially listed in Chinese Pharmacopoeia for authentication and quality assessment [3]. The previous prescreening biochemical analysis data showed the presence of alkaloids [5] and other compounds such as bibenzyls, phenanthrenes, polysaccharides, fluorenones and flavonoids in Dendrobium sp. [6]. Other phenolic acids and organic acids were also identified in Dendrobium sp. [7,8]. The reported pharmacological activities of Dendrobium species were diverse, including hepatic lipid and gluconeogenesis regulation [5], antioxidant [9], anti-inflammatory [5,9,10], antifungal [9,11], antimicrobial [9,12], anticancer [4,5,13], antimutagenic [9], antidiabetic [4,5,9], neuroprotective [4,5,9], immunomodulatory [4,9], antiplatelet aggregation [9] and antiviral [5,14]. Moreover, Dendrobium nobile is one of the TCM used to treat COVID-19 infection in northern China [15]. Thus, Dendrobium species is a potential plant for the lead discovery of drugs against SARS-CoV-2.
Various approaches for anti-SARS-CoV-2 drug discovery have been employed by blocking viral drug targets including viral entry, viral enzymes, viral replication, and viral translation and release [2]. Spike glycoprotein on the surface of SARS-CoV-2 is a potential drug target due to its crucial role in the first infection step. The S1 receptor-binding subunit and S2 membrane fusion subunit in the spike (S) protein are identified as viral proteins mediating virus entry into host cells [16]. The S1 subunit of the spike protein contains a receptor-binding domain (RBD) that recognizes and binds the human receptor angiotensin-converting enzyme 2 (hACE2). After the binding of the RBD in the S1 subunit to the hACE2, the next step is the S2 subunit-mediated membrane fusion of the viral envelope with the host-cell membrane [17]. The S1 subunit consists of the N-terminal domain (NTD, 14–305 aa), receptor-binding domain (RBD, 319–541 aa) and receptor binding motif (RBM, 437–508 aa) [18]. The RBM in the S1 subunit is crucial for the ACE2 binding as the amino acid residues in the RBM region contribute to the binding interactions of spike protein with the ACE2 receptor [19]. The SARS-CoV-2 spike protein, particularly the S1 subunit, has been used as a drug target in searching for anti-COVID-19 drugs. Several in silico screenings against the SARS-CoV-2 spike protein have been reported, but most used a compound library of existing drugs aimed at drug repurposing [20]. Herein, in silico screening of 83 compounds from Dendrobium sp. against the SARS-CoV-2 spike protein was performed and the lead compound, DB36, with promising antiviral infection, was identified.

2. Results

2.1. In Silico Screening Study

The in-house 83 compounds from Dendrobium sp. were compiled to build up a focus Dendrobium compound library. The chemotypes of compounds in the Dendrobium library are diverse, including flavonoid, flavonoid glycosides, phenolics, bibenzyls and bis(bibenzyls), phenanthrenes, bibenzyl-dihydrophenanthrenes, lignans, furanones, coumarins, chromones, acid and triterpenoids. These collected compounds were extracted from Dendrobium sp., including D. draconis, D. formosum, D. brymerianum, D. palpebrae, D. venustum, D. scabrilingue, D. parishii, D. parishii, D. ellipsophyllum, D. falconeri, D. pulchellum, D. tortile and D. capillipes. All compounds were docked with the spike protein subunit S1 (PDB code: 6VYB). The lowest binding free energy conformation (∆Gbinding) of the highest cluster was ranked and evaluated for the binding mode. The docking result revealed that all compounds bound with the S1-spike protein in seven different sites, as shown in Figure 1, with ∆Gbinding in a range of −11.89 to −4.06 Kcal/mol. Thirty compounds were found to interact with the amino acid residues at the receptor-binding motif (ACE2-RBM) of the receptor-binding domain (RBD). While twenty-five, two and one compounds are bound outside the ACE2-RBM at sites two, three and seven, respectively. However, these three binding sites were adjacent to the RBM and the binding may induce the conformational changes of RBM to be unable to bind to the ACE2 receptor. Other compounds bound to sites four, five and six outside the RBD.
The binding energy of all compounds was ranked by the free energy of binding. The top eight compounds with binding energy lower than −6.00 Kcal/mol, with the cluster over 35 conformations are shown in Table 1. The top four hit compounds (DB36, DB51, DB31 and DB40) bound at sites one and two were selected for the antivirus infectivity assay. The chemotype of these hits consists of dihydrophenanthrenes, fluorenones and phenanthrenes. The chemical structure of the four hit compounds are shown in Figure 2.

2.2. In Vitro Verifying Antiviral Activity of Hit Compounds against SARS-CoV-2 S–hACE2 Mediated Virus Infection

The antiviral activity against SARS-CoV-2 of hit compounds was evaluated by the in vitro assay model. The SARS-CoV-2 S pseudotyped HIV (carrying luciferase reporter gene) was used as a surrogate SARS-CoV-2 and human ACE2-TMPRSS2 expressing cells (hTMPRSS2 transfected HEK293T/17-hACE2 cells) as the host cells. The spike protein was used to bind with the ACE2 receptor on human host cells to initiate the infection process. After the SARS-CoV-2 S pseudotyped HIV infected the host cells, the luciferase substrate was catalyzed by the luciferase reporter enzyme resulting in luminescence. Thus, the luminescent signal directly correlates with the amount of viruses infecting or entering the host cell.
For the infectivity assay, the non-cytotoxic concentrations of four selected hit compounds were first determined by the cytotoxicity test at 1.56, 3.12, 6.25, 12.50, 25 and 50 μM. Compound DB36 showed the lowest toxicity, followed by DB40, DB51 and DB31 (Figure 3). The non-cytotoxic concentrations of each compound were used in the initial screening for antiviral infection at a concentration of 12.50 μM, except compound DB31, which was tested at a non-toxic concentration of 3.12 μM.
Antivirus infection activity of hit compounds was determined in the pre-incubation and co-incubation protocols. For pre-incubation, SARS-CoV-2 S pseudotyped HIV was incubated with the hit compound for one hour before being added to the host cells. While co-incubation, SARS-CoV-2 S pseudotyped HIV and hit compound were immediately added to the host cells. After incubation with host cells for 48 h, luminescence was determined. The results showed that compound DB36, 5-methoxy-7-hydroxy-9,10-dihydro-1,4-phenanthrenequinone, at a concentration of 12.5 µM, was able to reduce SARS-CoV-2 S pseudotyped HIV infectivity significantly compared to the control group, 0.5% DMSO, in both conditions of pre-incubation and co-incubation. In contrast, other hit compounds tested at the same concentration as compounds DB40 and DB51 and the lower concentration as compound DB31 had not reduced infection (Figure 4). In the case of co-incubation, compound DB36 had lower activity than pre-incubation, significantly (Figure 4).
Thus, compound DB36 was selected to determine the antiviral infection activity in a dose-response relationship for the estimation of the half-maximal inhibitory concentration (IC50) value. Interestingly, compound DB36 is effective against SARS-CoV-2 S infection in a dose-dependent manner in the pre-incubation condition. In contrast, the maximum inhibition of DB36 in co-incubation was only 35% at a concentration of 1.56 µM (Figure 5). In pre-incubation, the IC50 values against viral infection of DB36 were 6.87 µM, and the half-maximal cytotoxic concentration (CC50) was more than 50 µM, thus yielding a satisfactory selectivity index (SI) of more than 7.28 (Table 2). This hit compound showed antiviral infection at a concentration level of micromolar comparable to the reported repurposing drugs for SARS-CoV-2, such as hydroxychloroquine and sertraline [21].

2.3. DB36 Directly Inhibits SARS-CoV-2 S–hACE2 Binding

The insight-mediated mechanism for antivirus infectivity of compound DB36 was further investigated. The SARS-CoV-2 S–hACE2 binding assay was conducted to determine the effect of DB36 on the entry of SARS-CoV-2 into host cells at a molecular level. The result revealed that compound DB36 could inhibit the binding between the SARS-CoV-2 spike (RBD) protein and ACE2 receptor in a dose-dependent manner (Figure 6). The percent binding inhibition was 14.19 to 40.16% at a concentration of 200 to 1000 µM. The result suggested that the inhibition of SARS-CoV-2 spike–ACE2 binding mediated the antiviral infection activity of the hit compound DB36.

3. Discussion

The antivirus infectivity and spike binding assay results are in good agreement with the binding modes from the in silico experiment. The binding modes of hit compounds revealed that compound DB36 is fully bound with the amino acid residues in the spike protein at the RBM region. In contrast, other hit compounds are partially bound with amino acid residues at RBM of apo conformation spike protein (Figure 7A). The binding of DB36 at the chain–chain interface of the spike RBM-ACE2 complex plays an essential role in binding and stabilizing the complex structure of the virus spike protein and the ACE2 receptor of host cells, the first step of host entry [22]. DB36 interacted with the key amino acid residues in the RBM of the spike protein, namely Leu455, Phe456 and Phe490 (Figure 7C,D). Since these residues of the virus spike protein participated in H-bond formation with the ACE2 receptor for host entry, the binding of these residues by DB36 resulted in the inhibition of viruses binding with ACE2 and entering the host cells. The reported key amino acid residues of SARS-CoV-2 S-RBM providing H-bond interactions with ACE2 receptor were Leu455, Phe456, Ala475, Phe486, Phe490 and Gln493 and the amino acid residues for stabilizing the complex structure were Ser459, Gln474, and Pro499 [23]. The mutagenesis of these key amino acid residues resulted in a decrease in the binding affinity with the ACE2 receptor [23]. Notably, the amino acid residues Leu455 and Gln493 of the spike protein are crucial for forming hydrogen bonds with amino acid residues Lys31 and Glu35 of the ACE2 receptor [24].
Moreover, the located DB36 at RBM possibly obstructs or restricts the flexibility loop three of the spike protein to accommodate and stabilize the bound conformation of spike protein (Figure 7A,B). The three amino acids within flexible loop three including Phe486, Asn487 and Tyr489 were reported as stabilizing residues interacting with ACE2 (Figure 7B) [25,26]. This hinder of DB36 reduces the stabilization of bound conformation of spike protein and ACE2, leading to greater antiviral infectivity of pre-incubation over co-incubation. The binding at this flexible loop three was also found in some neutralizing antibodies designed to bind with RBD such as CC12.1 [27], P2C-1F11 [28], and S2E12 [29].
Thus, the most significant antivirus infectivity of DB36 among other hit compounds is possibly due to the fully bound in the RBM region and had interactions with the key residues Phe456 via a hydrogen bond and Leu455 and Ser459 via van der Waals (Figure 8A,B). Meanwhile, other hits DB31, DB40 and DB51 were partially bound with the RBM region of the spike protein and did not interact with key amino acids in the RBM region. The amino acid in the RBM region, in which DB31, DB40 and DB51 interacted, were Ser438, Leu441, Asp442, Lys444, Asn450, and/or Tyr451 (Figure 9 and Figure S1).
Although the inhibition results of DB36 on virus infectivity and the SARS-CoV-2 S–hACE2 binding appeared to be promising, structural optimization is needed to improve the potency. To increase the antivirus infection via anti-spike protein binding, the expansion of the binding area for more interactions with key residues at the binding interface of spike protein should be further carried out.

4. Materials and Methods

4.1. General

Molecular dockings were performed using AutoDockTools-1.5.6. All compounds were generated by Ultra 13.0 and ChemBio3D Ultra 13.0 and optimized using Gaussian 09 program. PyMOL program and Discovery Studio were used to create docking visualization and docking interaction. Microsoft Excel 2013 and GraphPad Prism version 5.02 were used to generate graph visualization and calculate IC50 values. Statistical analysis of cell viability for the antivirus infection activity study was conducted by one-way ANOVA using GraphPad Prism version 5.02.

4.2. In Silico Screening Study

4.2.1. Data Collection and Ligand Preparation

The structures of 83 compounds from Dendrobium sp. reported by our group (Supplement Table S1) were collected to construct an in-house library in 2D and 3D using ChemBioDraw and ChemBio3D. The ligands were optimized using the Gaussian 09 program with the B3LYP/6-31G (d, p) method. Then, Gasteiger’s charges were assigned using AutoDockTool-1.5.6.

4.2.2. Spike Protein Template Preparation

The spike protein of SARS-CoV-2 (PDB code: 6VYB) at 3.20 Å resolution was selected from the RCSB Protein Data Bank [30]. The open state domain of the trimer was separated to prepare a template. Water molecules were removed from the structure, and missing amino acid residues and hydrogen atoms were added to the system by BIOVIA Discovery Studio 2017 R2 Client. Gasteiger’s charges were assigned using AutoDockTool-1.5.6. A grid box was generated to cover the binding site and allosteric site of the S1 receptor-binding domain (amino acid residues 319–591) [31] using AutoGrid 4.0. The size of the grid was set as 126 × 100 × 100 Å3 with a grid spacing of 0.375 Å based on center (X, Y, Z) of 107.285, 180.579 and 208.827, respectively.

4.2.3. Docking and Interaction Visualization

The preparation ligands were docked with the spike protein template using AutoDockTool-1.5.6. The docking parameters were as follows: 100 runs of the GA, a population size of 300, energy evaluations per run of 2,500,000 and a maximum number of generations of 27,000. The best binding energy of the highest cluster of each compound was ranked. The binding interactions of ligand and the spike protein were visualized using PyMOL and Discovery Studio.

4.3. In Vitro Verification Assay

4.3.1. Preparation of Test Compounds

The test compounds, DB31 [32], DB36 [33,34], DB40 [32] and DB51 [35] were dissolved in dimethyl sulfoxide (DMSO), and diluted with DMSO to a desired concentration for in vitro assay.

4.3.2. Cell Lines and Pseudotyped Virus

Human embryonic kidney (HEK)293T/17 cells (ATCC: CRL11268) stably expressing a SARS-CoV-2 entry receptor of human cells, hACE2 (HEK293T/17-hACE2) were generated by lentivirus transduction as described previously [36,37] and maintained in Dulbecco’s Modified Eagle Medium/high glucose (Hyclone Laboratories, Logan, UT, USA) supplemented with 10% (v/v) fetal bovine serum and antibiotics [36,38].
The HIV-based lentivirus carrying a firefly luciferase reporter gene was pseudotyped with SARS-CoV-2 S protein (SARS-CoV-2 S pseudotyped HIV) by the method mentioned previously [36,39]. Briefly, the infectious viral particles were generated by co-transfection of pCSFLW, pCMV-ΔR8.91, and the pCAGGS plasmid carrying codon-optimized SARS-CoV-2 S gene (GenBank: YP_009724390.1) into HEK293T/17 cells. The supernatant containing SARS-CoV-2 S pseudotyped viral particles was harvested and stored at −80 °C until used.

4.3.3. Cytotoxicity Assay

HEK293T/17-hACE2 cells were seeded in a 96-well tissue culture microplate (4 × 104 cells/well) and incubated in a 5% CO2 incubator at 37 °C overnight. Each test compound was diluted with DMSO and added to the cells at the final concentrations of 1.56, 3.12, 6.25, 12.50, 25 and 50 µM. The final concentration of DMSO was normalized to 0.5% v/v to minimize the cytotoxic effect. DMSO-treated cells were used as a control to indicate 100% cell viability. After 48 h incubation, cytotoxicity was determined by adding Cell Counting Kit-8 reagent (Dojindo, Rockville, MD, USA) to the cells followed by incubation in a 5% CO2 incubator at 37 °C for 1 h. Then, the absorbance at 450 nm was measured by Synergy HTX Multi-Mode Microplate Reader (BioTek, Winooski, VT, USA). The percentage of cell viability was calculated by comparing the absorbance value of the test compound with DMSO as a control.

4.3.4. SARS-CoV-2 S–hACE2 Mediated Infectivity Assay

The SARS-CoV-2 S–hACE2 mediated virus entry system based on the neutralization assay [36,38] was used to determine the inhibitory effect of test compounds by infecting SARS-CoV-2 S pseudotyped HIV into the host cells, HEK293T/17-hACE2 cells overexpressing the human transmembrane serine protease 2 (hTMPRSS2), which are required for virus entry by fusion [40]. Briefly, the HEK293T/17-hACE2 cells (4.5 × 106 cells) were seeded in a 10 cm tissue culture dish overnight and transfected with 150 ng of pCAGGS plasmid carrying hTMPRSS2 gene (GenBank: BC051839.1) using FuGENE HD Transfection Reagent (Promega, Madison, WI, USA) for 24 h to allow the expression of hTMPRSS2. The pre-incubation protocol was performed by incubating 50 µL of SARS-CoV-2 S pseudotyped HIV (at 1 × 104 relative luminescence units) with 50 µL of medium containing test compound (at the non-cytotoxic concentration) in an opaque 96-well white microplate (PerkinElmer, Waltham, MA, USA) at 37 °C for 1 h. Then, the HEK293T/17-hACE2 cells overexpressing hTMPRSS2 were trypsinized and resuspended in a fresh medium at a density of 1 × 106 cells/mL. Fifty microliters of the cell suspension were added to the compound-treated virus. The cells were incubated in a 5% CO2 incubator at 37 °C for 48 h to allow infection and the luciferase reporter gene expression. The DMSO-treated SARS-CoV-2 S pseudotyped HIV was used as a control to define 100% infectivity and the monoclonal antibody against SARS-CoV-2 receptor-binding domain (RBD). MonoRab SARS-CoV-2 Neutralizing Antibody (BS-R2B2) (GenScript, Piscataway NJ, USA) was used as a positive control. Then, luciferase activity was determined using Bright-Glo Luciferase Assay System (Promega) by removing the culture medium and adding 25 µL of PBS-diluted luciferase assay substrate (ratio 1:1) to the infected cells and incubating the cells at room temperature for 5 min. The luminescence signal was measured by Synergy HTX Multi-Mode Microplate Reader (BioTek). The percentage of SARS-CoV-2 S-hACE2 mediated infectivity was calculated by comparing the luciferase activity of the test compound with DMSO as a control. The co-incubation protocol was performed by adding HEK293T/17-hACE2 cells overexpressing hTMPRSS2 into the mixture of the test compound and SARS-CoV-2 S pseudotyped HIV without pre-incubation for 1 h.

4.3.5. SARS-CoV-2 S–hACE2 Binding Inhibition Assay

The direct inhibitory effect of test compounds on SARS-CoV-2 S–hACE2 binding was determined by ELISA using the SARS-CoV-2 S RBD-coated 96-well strip microplate from the COVID-19 Spike-ACE2 binding assay kit (RayBiotech, Peachtree Corners, GA, USA). Briefly, the 1x ACE2 Protein was mixed with the test compound at different concentrations (by normalizing the final concentration of DMSO solvent to 5% v/v) and added to the spike RBD-coated plate for 2.5 h incubation at room temperature. The COVID-19 Spike-ACE2 Binding Assay Kit Controls (RayBiotech), which are the purified antibodies that do not inhibit or inhibit SARS-CoV-2 S–ACE2 binding, were used as negative and positive controls, respectively. The strip microplate was washed with 1x Wash Solution, incubated with 1x Detection Antibody followed by incubation with 1x HRP-Conjugated Anti-IgG, TMB substrate, and stop solution according to the manufacturer’s protocol. The absorbance at 450 nm was measured using Synergy HTX Multi-Mode Microplate Reader (BioTek). The percentage of SARS-CoV-2 S–hACE2 binding was calculated by comparing the absorbance value of the test compound with a negative control.

5. Conclusions

The in silico study of the SARS-CoV-2 spike protein can be used as a screening tool to identify a new lead compound to treat COVID-19. The new lead compound DB36, 5-methoxy-7-hydroxy-9,10-dihydro-1,4-phenanthrenequinone, found in D. draconis [33] and D. formosum [34] was identified to inhibit virus infection with an IC50 value of 6.87 µM. The mechanism mediated antivirus infection appeared to inhibit the SARS-CoV-2 spike protein (RBD) from binding to the ACE2 receptor. The in silico binding study suggested that the binding interactions with the residues in the RBM region of the spike S1 subunit, particularly the interface area, play an essential role in antivirus infectivity. The discovery of antiviral infection activity of DB36 and its mediated mechanism supports the use of D. draconis and D. formosum for COVID-19 treatment. Similar to DB36, docking results revealed that p-hydroxybenzoic acid and (-)-shikimic acid bound with comparable binding energy at the same binding site. In summary, this is the first report showing the potential of both compounds against SARS-CoV-2 infection. Structural modification of the two compounds is needed to optimize binding affinity and enhance antiviral activity.

Supplementary Materials

The following supporting information can be downloaded at: https://0-www-mdpi-com.brum.beds.ac.uk/article/10.3390/ph15050620/s1, Table S1: The structures of 83 compounds from Dendrobium sp. docked against SARS-CoV-2 spike protein; Figure S1: Binding modes of DB31, DB40 and DB51 located in the S1-RBD of spike protein adjacent to the binding motif (RBM) region as shown in an orange color.

Author Contributions

Conceptualization, O.V. and P.R.; methodology, O.V. and P.R.; formal analysis, J.J., W.Y. and N.C.; investigation, J.J., W.Y. and N.C.; resources, O.V., B.S. and W.T.; data curation, J.J.; writing—original draft preparation, J.J. and N.C.; writing—review and editing, J.J., N.C., P.R. and O.V.; visualization, J.J. and W.Y.; supervision, O.V.; project administration, O.V.; funding acquisition, O.V. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the National Research Council of Thailand under grant Molecular Probes for Imaging Research Network IRN FY2020 507/2563, grant number N10A650046.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

This project is funded by the National Research Council of Thailand under grant Molecular Probes for Imaging Research Network IRN FY2020 507/2563 (O.V.). Part of this research was supported by the Center of Excellence for Innovation in Analytical Science and Technology for a Biodiversity-Based Economic and Society (I-ANALY-S-T_B.BES-CMU), Chiang Mai University, Chiang Mai, Thailand. We appreciate Anan Jongkaewwattana and Kanjana Srisutthisamphan (National Center for Genetic Engineering and Biotechnology) for providing the SARS-CoV-2 S pseudotyped virus and HEK293T/17-hACE2 cells for the infectivity assay.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Abiri, R.; Abdul-Hamid, H.; Sytar, O.; Abiri, R.; de Almeida, E.B.; Sharma, S.; Bulgakov, V.; Arroo, R.; Malik, S. A Brief Overview of Potential Treatments for Viral Diseases Using Natural Plant Compounds: The Case of SARS-CoV. Molecules 2021, 26, 3868. [Google Scholar] [CrossRef] [PubMed]
  2. Asselah, T.; Durantel, D.; Pasmant, E.; Lau, G.; Schinazi, R.F. COVID-19: Discovery, diagnostics and drug development. J. Hepatol. 2020, 74, 168–184. [Google Scholar] [CrossRef] [PubMed]
  3. Xu, J.; Han, Q.-B.; Li, S.-L.; Chen, X.-J.; Wang, X.-N.; Zhao, Z.-Z.; Chen, H.-B. Chemistry, bioactivity and quality control of Dendrobium, a commonly used tonic herb in traditional Chinese medicine. Phytochem. Rev. 2013, 12, 341–367. [Google Scholar] [CrossRef]
  4. Cakova, V.; Bonte, F.; Lobstein, A. Dendrobium: Sources of Active Ingredients to Treat Age-Related Pathologies. Aging Dis. 2017, 8, 827–849. [Google Scholar] [CrossRef] [Green Version]
  5. Mou, Z.; Zhao, Y.; Ye, F.; Shi, Y.; Kennelly, E.J.; Chen, S.; Zhao, D. Identification, Biological Activities and Biosynthetic Pathway of Dendrobium Alkaloids. Front. Pharmacol. 2021, 12, 605994. [Google Scholar] [CrossRef]
  6. Nam, B.; Jang, H.J.; Han, A.R.; Kim, Y.R.; Jin, C.H.; Jung, C.H.; Kang, K.B.; Kim, S.H.; Hong, M.J.; Kim, J.B.; et al. Chemical and biological profiles of Dendrobium in two different species, Their hybrid, and gamma-irradiated mutant lines of the hybrid based on LC-QToF MS and cytotoxicity analysis. Plants 2021, 10, 1376. [Google Scholar] [CrossRef]
  7. Chang, C.-C.; Ku, A.F.; Tseng, Y.-Y.; Yang, W.-B.; Fang, J.-M.; Wong, C.-H. 6,8-Di-C-glycosyl Flavonoids from Dendrobium huoshanense. J. Nat. Prod. 2010, 73, 229–232. [Google Scholar] [CrossRef]
  8. Yoo, S.-R.; Jeong, S.-J.; Lee, N.-R.; Shin, H.-K.; Seo, C.-S. Simultaneous determination and anti-inflammatory effects of four phenolic compounds in Dendrobii Herba. Nat. Prod. Res. 2017, 31, 2923–2926. [Google Scholar] [CrossRef]
  9. Lam, Y.; Ng, T.B.; Yao, R.M.; Shi, J.; Xu, K.; Sze, S.C.W.; Zhang, K.Y. Evaluation of Chemical Constituents and Important Mechanism of Pharmacological Biology in Dendrobium Plants. Evid. Based Complement. Altern. Med. 2015, 2015, 841752. [Google Scholar] [CrossRef] [Green Version]
  10. Lin, Y.; Wang, F.; Yang, L.-J.; Chun, Z.; Bao, J.-K.; Zhang, G.-L. Anti-inflammatory phenanthrene derivatives from stems of Dendrobium denneanum. Phytochemistry 2013, 95, 242–251. [Google Scholar] [CrossRef]
  11. Sattayasai, N.; Sudmoon, R.; Nuchadomrong, S.; Chaveerach, A.; Kuehnle, A.R.; Mudalige-Jayawickrama, R.G.; Bunyatratchata, W. Dendrobium findleyanum agglutinin: Production, localization, anti-fungal activity and gene characterization. Plant Cell Rep. 2009, 28, 1243–1252. [Google Scholar] [CrossRef] [PubMed]
  12. Xing, Y.M.; Chen, J.; Cui, J.L.; Chen, X.M.; Guo, S.X. Antimicrobial activity and biodiversity of endophytic fungi in Dendrobium devonianum and Dendrobium thyrsiflorum from Vietnam. Curr. Microbiol. 2011, 62, 1218–1224. [Google Scholar] [CrossRef]
  13. Sun, J.; Guo, Y.; Fu, X.; Wang, Y.; Liu, Y.; Huo, B.; Sheng, J.; Hu, X. Dendrobium candidum inhibits MCF-7 cells proliferation by inducing cell cycle arrest at G2/M phase and regulating key biomarkers. Onco. Targets Ther. 2016, 9, 21–30. [Google Scholar] [PubMed] [Green Version]
  14. Li, R.; Liu, T.; Liu, M.; Chen, F.; Liu, S.; Yang, J. Anti-influenza A Virus Activity of Dendrobine and Its Mechanism of Action. J. Agric. Food Chem. 2017, 65, 3665–3674. [Google Scholar] [CrossRef] [PubMed]
  15. Yang, Y.; Islam, M.S.; Wang, J.; Li, Y.; Chen, X. Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): A review and perspective. Int. J. Biol. Sci. 2020, 16, 1708–1717. [Google Scholar] [CrossRef]
  16. Li, W.; Moore, M.J.; Vasilieva, N.; Sui, J.; Wong, S.K.; Berne, M.A.; Somasundaran, M.; Sullivan, J.L.; Luzuriaga, K.; Greenough, T.C.; et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003, 426, 450–454. [Google Scholar] [CrossRef] [Green Version]
  17. Zhou, P.; Yang, X.-L.; Wang, X.-G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H.-R.; Zhu, Y.; Li, B.; Huang, C.-L.; et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020, 579, 270–273. [Google Scholar] [CrossRef] [Green Version]
  18. Xia, S.; Liu, M.; Wang, C.; Xu, W.; Lan, Q.; Feng, S.; Qi, F.; Bao, L.; Du, L.; Liu, S.; et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 2020, 30, 343–355. [Google Scholar] [CrossRef] [Green Version]
  19. Shang, J.; Ye, G.; Shi, K.; Wan, Y.; Luo, C.; Aihara, H.; Geng, Q.; Auerbach, A.; Li, F. Structural basis of receptor recognition by SARS-CoV-2. Nature 2020, 581, 221–224. [Google Scholar] [CrossRef] [Green Version]
  20. Maffucci, I.; Contini, A. In silico drug repurposing for SARS-CoV-2 main proteinase and spike proteins. J. Proteome Res. 2020, 19, 4637–4648. [Google Scholar] [CrossRef]
  21. Xiao, X.; Wang, C.; Chang, D.; Wang, Y.; Dong, X.; Jiao, T.; Zhao, Z.; Ren, L.; Dela Cruz, C.S.; Sharma, L.; et al. Identification of potent and safe antiviral therapeutic candidates against SARS-CoV-2. Front. Immunol. 2020, 11, 586572. [Google Scholar] [CrossRef] [PubMed]
  22. Cagliani, R.; Forni, D.; Clerici, M.; Sironi, M. Computational Inference of Selection Underlying the Evolution of the Novel Coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2. J. Virol. 2020, 94, e00411-20. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Yi, C.; Sun, X.; Ye, J.; Ding, L.; Liu, M.; Yang, Z.; Lu, X.; Zhang, Y.; Ma, L.; Gu, W.; et al. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. Cell Mol. Immunol. 2020, 17, 621–630. [Google Scholar] [CrossRef] [PubMed]
  24. Lan, J.; Ge, J.; Yu, J.; Shan, S.; Zhou, H.; Fan, S.; Zhang, Q.; Shi, X.; Wang, Q.; Zhang, L.; et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 2020, 581, 215–220. [Google Scholar] [CrossRef] [Green Version]
  25. Laurini, E.; Marson, D.; Aulic, S.; Fermeglia, M.; Pricl, S. Computational alanine scanning and structural analysis of the SARS-CoV-2 spike protein/angiotensin-converting enzyme 2 complex. ACS Nano 2020, 14, 11821–11830. [Google Scholar] [CrossRef]
  26. Williams, J.K.; Wang, B.; Sam, A.; Hoop, C.L.; Case, D.A.; Baum, J. Molecular dynamics analysis of a flexible loop at the binding interface of the SARS-CoV-2 spike protein receptor-binding domain. Proteins 2021, 90, 1044–1053. [Google Scholar] [CrossRef]
  27. Yuan, M.; Liu, H.; Wu, N.C.; Lee, C.C.D.; Zhu, X.; Zhao, F.; Huang, D.; Yu, W.; Hua, Y.; Tien, H.; et al. Structural basis of a shared antibody response to SARS-CoV-2. Science 2020, 369, 1119–1123. [Google Scholar] [CrossRef]
  28. Ge, J.; Wang, R.; Ju, B.; Zhang, Q.; Sun, J.; Chen, P.; Zhang, S.; Tian, Y.; Shan, S.; Cheng, L.; et al. Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry. Nat. Commun. 2021, 12, 250. [Google Scholar] [CrossRef]
  29. Tortorici, M.A.; Beltramello, M.; Lempp, F.A.; Pinto, D.; Dang, H.V.; Rosen, L.E.; McCallum, M.; Bowen, J.; Minola, A.; Jaconi, S.; et al. Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. Science 2020, 370, 950–957. [Google Scholar] [CrossRef]
  30. Walls, A.C.; Park, Y.J.; Tortorici, M.A.; Wall, A.; McGuire, A.T.; Veesler, D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020, 181, 281–292. [Google Scholar] [CrossRef]
  31. Wrapp, D.; Wang, N.; Corbett, K.S.; Goldsmith, J.A.; Hsieh, C.-L.; Abiona, O.; Graham, B.S.; McLellan, J.S. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020, 367, 1260–1263. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Sukphan, P.; Sritularak, B.; Mekboonsonglarp, W.; Lipipun, V.; Likhitwitayawuid, K. Chemical Constituents of Dendrobium venustum and their Antimalarial and Anti-herpetic Properties. Nat. Prod. Commun. 2014, 9. [Google Scholar] [CrossRef] [Green Version]
  33. Sritularak, B.; Anuwat, M.; Likhitwitayawuid, K. A new phenanthrenequinone from Dendrobium draconis. J. Asian Nat. Prod. Res. 2011, 13, 251–255. [Google Scholar] [CrossRef]
  34. Inthongkaew, P.; Chatsumpun, N.; Supasuteekul, C.; Kitisripanya, T.; Putalun, W.; Likhitwitayawuid, K.; Sritularak, B. α-Glucosidase and pancreatic lipase inhibitory activities and glucose uptake stimulatory effect of phenolic compounds from Dendrobium formosum. Rev. Bras. Farm. 2017, 27, 480–487. [Google Scholar] [CrossRef]
  35. Klongkumnuankarn, P.; Busaranon, K.; Chanvorachote, P.; Sritularak, B.; Jongbunprasert, V.; Likhitwitayawuid, K. Cytotoxic and Antimigratory Activities of Phenolic Compounds from Dendrobium brymerianum. Evid. Based Complement. Altern. Med. 2015, 2015, 350410. [Google Scholar] [CrossRef] [Green Version]
  36. Koonpaew, S.; Kaewborisuth, C.; Srisutthisamphan, K.; Wanitchang, A.; Thaweerattanasinp, T.; Saenboonrueng, J.; Poonsuk, S.; Jengarn, J.; Viriyakitkosol, R.; Kramyu, J.; et al. A single-cycle influenza a virus-based SARS-CoV-2 vaccine elicits potent immune responses in a mouse model. Vaccines 2021, 9, 850. [Google Scholar] [CrossRef] [PubMed]
  37. Sungsuwan, S.; Jongkaewwattana, A.; Jaru-Ampornpan, P. Nucleocapsid proteins from other swine enteric coronaviruses differentially modulate PEDV replication. Virology 2019, 540, 45–56. [Google Scholar] [CrossRef]
  38. Ferrara, F.; Temperton, N. Pseudotype Neutralization Assays: From Laboratory Bench to Data Analysis. Methods Protoc. 2018, 1, 8. [Google Scholar] [CrossRef] [Green Version]
  39. Grehan, K.; Ferrara, F.; Temperton, N. An optimised method for the production of MERS-CoV spike expressing viral pseudotypes. MethodsX 2015, 2, 379–384. [Google Scholar] [CrossRef]
  40. Hoffmann, M.; Kleine-Weber, H.; Schroeder, S.; Krüger, N.; Herrler, T.; Erichsen, S.; Schiergens, T.S.; Herrler, G.; Wu, N.H.; Nitsche, A.; et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020, 181, 271–280. [Google Scholar] [CrossRef]
Pharmaceuticals 15 00620 g001 550
Figure 1. The binding sites of 83 in-house library compounds from Dendrobium sp. The orange surface is the receptor-binding motif (RBM) of amino acid residues 437–508.
Figure 1. The binding sites of 83 in-house library compounds from Dendrobium sp. The orange surface is the receptor-binding motif (RBM) of amino acid residues 437–508.
Pharmaceuticals 15 00620 g001
Pharmaceuticals 15 00620 g002 550
Figure 2. The chemical structures of hit compounds arising from the virtual screening.
Figure 2. The chemical structures of hit compounds arising from the virtual screening.
Pharmaceuticals 15 00620 g002
Pharmaceuticals 15 00620 g003 550
Figure 3. Cytotoxicity of identified hit compounds from in silico screening. HEK293T/17-hACE2 cells were treated with DB31, DB36, DB40, and DB51 at concentrations of 1.56, 3.12, 6.25, 12.50, 25 and 50 μM for 48 h. Cell viability was determined by Cell Counting Kit-8 solution at the optical density of 450 nm. Percent cell viability was calculated by comparing with DMSO. Data are expressed as the relative mean value with an error bar (standard error of the mean, SEM) from three independent experiments (each performed in triplicate).
Figure 3. Cytotoxicity of identified hit compounds from in silico screening. HEK293T/17-hACE2 cells were treated with DB31, DB36, DB40, and DB51 at concentrations of 1.56, 3.12, 6.25, 12.50, 25 and 50 μM for 48 h. Cell viability was determined by Cell Counting Kit-8 solution at the optical density of 450 nm. Percent cell viability was calculated by comparing with DMSO. Data are expressed as the relative mean value with an error bar (standard error of the mean, SEM) from three independent experiments (each performed in triplicate).
Pharmaceuticals 15 00620 g003
Pharmaceuticals 15 00620 g004 550
Figure 4. Screening of hit compounds against pseudovirion (SARS-CoV-2 S pseudotyped HIV) infection to host cells, HEK293T, at a concentration of 12.50 μM with the exception of DB31 at a concentration of 3.12 μM. Confluent HEK293T/17-hACE2 cells overexpressing hTMPRSS2 were incubated with pseudovirion and hit compounds in pre-incubation conditions (virus and the hit compound incubated for one hour before infected to the cell) or co-incubation (virus and the hit compound immediately infected to the cells). BS-R2B2 (MonoRab SARS-CoV-2 neutralizing antibody) at 1 µg/mL was used as a positive control. The percentage of infectivity of each bar presented the percentage of SARS-CoV-2 S-hACE2 mediated infectivity as mean ± SEM (n = 3). The letter ‘a’ denotes a significant difference compared with the control DMSO (p < 0.05), and the symbol ‘#’ denotes a significant difference between pre- and co-incubation of each compound, based on one-way ANOVA using GraphPad Prism 5.02.
Figure 4. Screening of hit compounds against pseudovirion (SARS-CoV-2 S pseudotyped HIV) infection to host cells, HEK293T, at a concentration of 12.50 μM with the exception of DB31 at a concentration of 3.12 μM. Confluent HEK293T/17-hACE2 cells overexpressing hTMPRSS2 were incubated with pseudovirion and hit compounds in pre-incubation conditions (virus and the hit compound incubated for one hour before infected to the cell) or co-incubation (virus and the hit compound immediately infected to the cells). BS-R2B2 (MonoRab SARS-CoV-2 neutralizing antibody) at 1 µg/mL was used as a positive control. The percentage of infectivity of each bar presented the percentage of SARS-CoV-2 S-hACE2 mediated infectivity as mean ± SEM (n = 3). The letter ‘a’ denotes a significant difference compared with the control DMSO (p < 0.05), and the symbol ‘#’ denotes a significant difference between pre- and co-incubation of each compound, based on one-way ANOVA using GraphPad Prism 5.02.
Pharmaceuticals 15 00620 g004
Pharmaceuticals 15 00620 g005 550
Figure 5. DB36 inhibits SARS-CoV-2 S-hACE2 mediated virus entry in a dose-dependent manner. SARS-CoV-2 S pseudotyped HIV was pre-incubated with DB36 at a concentration of 0.78, 1.56, 3.12, 6.25, 12.50, and 25.00 µM for one hour and infected to HEK293T/17-hACE2 overexpressing hTMPRSS2 (pre-incubation) or immediately infected to the cells (co-incubation). Infectivity of the virus was determined by measuring the activity of expressed luciferase reporter gene. Data are expressed as the relative mean value with an error bar (SEM) from 2–3 independent experiments (each performed in triplicate).
Figure 5. DB36 inhibits SARS-CoV-2 S-hACE2 mediated virus entry in a dose-dependent manner. SARS-CoV-2 S pseudotyped HIV was pre-incubated with DB36 at a concentration of 0.78, 1.56, 3.12, 6.25, 12.50, and 25.00 µM for one hour and infected to HEK293T/17-hACE2 overexpressing hTMPRSS2 (pre-incubation) or immediately infected to the cells (co-incubation). Infectivity of the virus was determined by measuring the activity of expressed luciferase reporter gene. Data are expressed as the relative mean value with an error bar (SEM) from 2–3 independent experiments (each performed in triplicate).
Pharmaceuticals 15 00620 g005
Pharmaceuticals 15 00620 g006 550
Figure 6. The spike RBD and ACE2 binding inhibition of DB36 in a dose-dependent manner. Data are expressed as the relative mean value with an error bar (SEM) from three independent experiments (each performed in duplicate). BS-R2B2 (MonoRab SARS-CoV-2 neutralizing antibody) at 1 µg/mL was used as a positive control. The letter ‘a’ denotes a significant difference compared with the negative control (p < 0.05) based on one-way ANOVA using GraphPad Prism 5.02.
Figure 6. The spike RBD and ACE2 binding inhibition of DB36 in a dose-dependent manner. Data are expressed as the relative mean value with an error bar (SEM) from three independent experiments (each performed in duplicate). BS-R2B2 (MonoRab SARS-CoV-2 neutralizing antibody) at 1 µg/mL was used as a positive control. The letter ‘a’ denotes a significant difference compared with the negative control (p < 0.05) based on one-way ANOVA using GraphPad Prism 5.02.
Pharmaceuticals 15 00620 g006
Pharmaceuticals 15 00620 g007 550
Figure 7. Binding mode of DB36 (green color stick) located in the binding motif (RBM) region (orange color surface) at the interface area of the spike protein interacting with ACE2 receptor (cyan helix color): (A) Binding location of DB36 at RBD of apo conformation of spike protein comparing with other hits; (B) The superimposition of the docked pose of DB36 with the ACE2 bound conformation of the spike protein (PDB code: 7KMB, pink color); The red arrow showed the flexible loop three (residues 472–490) of the spike protein in conformations of (A) apo (orange color) and (B) ACE2 bound (pink color); (C,D) The interactions of DB36 with the residues at the interface area of the spike protein interacting with the ACE2 receptor.
Figure 7. Binding mode of DB36 (green color stick) located in the binding motif (RBM) region (orange color surface) at the interface area of the spike protein interacting with ACE2 receptor (cyan helix color): (A) Binding location of DB36 at RBD of apo conformation of spike protein comparing with other hits; (B) The superimposition of the docked pose of DB36 with the ACE2 bound conformation of the spike protein (PDB code: 7KMB, pink color); The red arrow showed the flexible loop three (residues 472–490) of the spike protein in conformations of (A) apo (orange color) and (B) ACE2 bound (pink color); (C,D) The interactions of DB36 with the residues at the interface area of the spike protein interacting with the ACE2 receptor.
Pharmaceuticals 15 00620 g007
Pharmaceuticals 15 00620 g008 550
Figure 8. Binding mode of DB36 (green color) located in the binding motif (RBM) region: (A) surface view of DB36 binding mode; (B) amino acid interactions of DB36.
Figure 8. Binding mode of DB36 (green color) located in the binding motif (RBM) region: (A) surface view of DB36 binding mode; (B) amino acid interactions of DB36.
Pharmaceuticals 15 00620 g008
Pharmaceuticals 15 00620 g009 550
Figure 9. Binding modes of DB31 located in the S1-RBD of the spike protein adjacent to the binding motif (RBM) region in an orange color surface: (A) surface view of DB31 binding position between RBM (orange color) and RBD (gray color) regions; (B) amino acid interactions of DB31.
Figure 9. Binding modes of DB31 located in the S1-RBD of the spike protein adjacent to the binding motif (RBM) region in an orange color surface: (A) surface view of DB31 binding position between RBM (orange color) and RBD (gray color) regions; (B) amino acid interactions of DB31.
Pharmaceuticals 15 00620 g009
Table
Table 1. Docking result of the top-ranking compounds from Dendrobium sp. against the SARS-CoV-2 spike protein.
Table 1. Docking result of the top-ranking compounds from Dendrobium sp. against the SARS-CoV-2 spike protein.
CodeNumber
in Cluster		∆Gbinding (Kcal/mol)Site
Number		CompoundChemotype
DB3635−8.0915-Methoxy-7-hydroxy-9,10-dihydro-1,4-phenanthrenequinoneDihydro
phenanthrenes
DB5168−7.852DendroflorinFluorenones
DB3175−7.742Densiflorol BPhenanthrenes
DB4044−6.922LusianthridinDihydro
phenanthrenes
DB5051−6.72NobiloneFluorenones
DB3044−6.692FlavanthrininPhenanthrenes
DB6536−6.151p-Hydroxybenzoic acidPhenolics
DB7438−6.061(-)-Shikimic acidAcids
Table
Table 2. Antiviral infection activity of hit compounds.
Table 2. Antiviral infection activity of hit compounds.
CompoundsConcentration (µM)% Infection ± SEMIC50
(µM)		CC50
(µM)		SI
(CC50/IC50)
DB313.12110.81 ± 5.41-11.85-
DB3612.5031.57 ± 2.376.87>50>7.28
DB4012.5085.23 ± 6.37->50-
DB5112.5081.98 ± 5.83->50-
Hydroxychloroquine--1.33 a>30 a>22.56 a
Sertraline--9.34 a27.84 a2.98 a
a Ref: [21].
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Jiaranaikulwanitch, J.; Yooin, W.; Chutiwitoonchai, N.; Thitikornpong, W.; Sritularak, B.; Rojsitthisak, P.; Vajragupta, O. Discovery of Natural Lead Compound from Dendrobium sp. against SARS-CoV-2 Infection. Pharmaceuticals 2022, 15, 620. https://0-doi-org.brum.beds.ac.uk/10.3390/ph15050620

AMA Style

Jiaranaikulwanitch J, Yooin W, Chutiwitoonchai N, Thitikornpong W, Sritularak B, Rojsitthisak P, Vajragupta O. Discovery of Natural Lead Compound from Dendrobium sp. against SARS-CoV-2 Infection. Pharmaceuticals. 2022; 15(5):620. https://0-doi-org.brum.beds.ac.uk/10.3390/ph15050620

Chicago/Turabian Style

Jiaranaikulwanitch, Jutamas, Wipawadee Yooin, Nopporn Chutiwitoonchai, Worathat Thitikornpong, Boonchoo Sritularak, Pornchai Rojsitthisak, and Opa Vajragupta. 2022. "Discovery of Natural Lead Compound from Dendrobium sp. against SARS-CoV-2 Infection" Pharmaceuticals 15, no. 5: 620. https://0-doi-org.brum.beds.ac.uk/10.3390/ph15050620

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop